Correction: MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity.

[This corrects the article DOI: 10.1371/journal.pgen.1010171.].

Fig 3 is incorrect. [1] In panels F and G, Mdm2-/- should be Mdm2+/+. The authors have provided a corrected version here.

Fig 3

p53-null Mdm2 MEFs and sarcoma cells have defects in and increased and G2-M transition hyperploidy.

(A) Cell cycle profiles of Mdm2: TP53 and Mdm2: TP53 MEFs (passage 6) by flow cytometry. Dip, diploid, An, aneuploid. (B) Increased phospho-Histone 3 at Serine 10 (pH3(S10) in p53-deficient Mdm2 sarcoma tissues. Representative histochemical staining of pH3(S10) (a, b) and Ki67 (c, d) in sarcoma tissues from p53: Mdm2 (a, c) or p53: Mdm2 (b, d) mice. Left images at 10x magnification and at 40x magnification of image areas in frame shown on the right. (C) Quantitative analysis of pH3(S10) staining in two p53: Mdm2 and three p53: Mdm2 sarcoma samples. *, t test, p = 0.0106. (D) Quantitative analysis of Ki67-positive cells in two p53: Mdm2 and three p53: Mdm2 sarcoma samples. ns, t test, p = 0.604. (E) Mdm2-tetp53 and Mdm2-tetp53 MEFs were used for BrdU labeling experiments. Gating settings are shown to define viable, singlet and BrdU-positive cells. (F) Diploid S (Dip S) and hyperploid S (Hyp S) fractions of Mdm2-tetp53 and Mdm2-tetp53 MEFs were presented. (G) Diploid S (Dip S) and hyperploid S (Hyp S) fractions of etoposide-treated (5μM, 24h) Mdm2-tetp53 and Mdm2-tetp53 MEFs were shown.